<DOC>
	<DOCNO>NCT01724515</DOCNO>
	<brief_summary>The purpose study determine much fat body decrease conversion food energy energy body use .</brief_summary>
	<brief_title>PGC-1 Mitochondrial Dysfunction Diabetes</brief_title>
	<detailed_description>The investigator ' prior research focus define change expression nuclear encode mitochondrial gene predict change insulin sensitivity skeletal muscle , goal define molecular mechanism underlie connection mitochondrial dysfunction insulin resistance skeletal muscle . The purpose study determine whether experimental lipid oversupply decrease mitochondrial respiratory function . We use mitochondrial respiration study vitro mass spectrometry proteomics analysis test hypothesis experimental lipid oversupply : 1 . Decreases mitochondrial respiration response lipid fuel . 2 . Reduces abundance mitochondrial protein . 3 . Alters phosphorylation protein electron transport chain . Three group subject study : lean , healthy control subject ( n=12 ) , obese non-diabetic subject ( n=12 ) patient type 2 Diabetes Mellitus ( n=12 ) total 36 subject . Twenty subject complete study Arizona State University ; remain 16 subject accrue Mayo Clinic Arizona . Subjects come Mayo Clinic 2 time . On study Day 1 subject screen medical history physical exam , 75 g oral glucose tolerance test , measure body fat percentage , electrocardiogram ( EKG ) . On Study Day 2 , subject report clinic overnight fast . Female subject take urine pregnancy test . A muscle biopsy perform take small sample one thigh . A lipid infusion perform 5 hour ( 60 ml/hr ) , blood sample take 8 interval infusion . At end 5 hour period , second muscle biopsy take thigh . The fat infusion stop , subject give lunch allow leave clinic .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1 . Subjects must able communicate meaningfully investigator must legally competent provide write informed consent . 2 . Subjects may either sex age describe protocol . Female subject must nonlactating eligible negative pregnancy test throughout study period . 3 . Subjects must range age describe specific protocol . 4 . Subjects must follow laboratory value : 1 . Hematocrit ≥ 35 vol % 2 . Serum creatinine ≤ 1.6 mg/dl 3 . Aspartate Aminotransferase ( AST ) ( SGOT ) &lt; 2 time upper limit normal 4 . Alanine Aminotransferase ( ALT ) ( SGPT ) &lt; 2 time upper limit normal 5 . Alkaline phosphatase &lt; 2 time upper limit normal 6 . Triglycerides &lt; 150 mg/dl . 7 . Prothrombin Time ( PT ) 11.7 14.3 second ( Intralipid/heparin infusion , PT determine insure &lt; 1.52.0 time normal value . ) 8 . Partial Thromboplastin Time ( PTT ) 23.037.0 second . 1 . Subjects must receive follow medication : thiazide furosemide diuretic , betablockers , chronic medication know adverse effect glucose tolerance level unless patient stable dose agent past three month entry study . Subjects may take stable dose estrogens hormonal replacement therapy , subject agent prior three month . Subjects take systemic glucocorticoid exclude . 2 . Subjects history clinically significant heart disease ( New York Heart Classification great grade II ; nonspecific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) study . 3 . Recent systemic pulmonary embolus , untreated highrisk proliferative retinopathy , recent retinal hemorrhage , uncontrolled hypertension , systolic BP &gt; 180 , diastolic BP &gt; 105 , autonomic neuropathy , rest heart rate &gt; 100 , electrolyte abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>